References
1. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et
al. Estimation of the asymptomatic ratio of novel coronavirus infections
(COVID-19). Int J Infect Dis. 2020;94:154-5.
2. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the
asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on
board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro
Surveill. 2020;25(10).
3. Sawano T, Ozaki A, Rodriguez-Morales AJ, Tanimoto T, Sah R. Limiting
spread of COVID-19 from cruise ships: lessons to be learnt from Japan.
QJM. 2020;113(5):309-10.
4. Lin Q, Zhao S, Gao D, Lou Y, Yang S, Musa SS, et al. A conceptual
model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan,
China with individual reaction and governmental action. Int J Infect
Dis. 2020;93:211-6.
5. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus
Disease 2019 (COVID-19): A Perspective from China. Radiology.
2020;296(2):E15-E25.
6. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and
Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients
With SARS-CoV-2 Infection in a Community Treatment Center in the
Republic of Korea. JAMA Intern Med. 2020.
7. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al.
Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a
Long-Term Care Skilled Nursing Facility - King County, Washington, March
2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):377-81.
8. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a
Report of 72314 Cases From the Chinese Center for Disease Control and
Prevention. JAMA. 2020;323(13):1239-42.
9. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as
coronavirus disease 2019 (COVID-19) pandemic: A global health emergency.
Sci Total Environ. 2020;730:138996.
10. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH,
et al. The implications of silent transmission for the control of
COVID-19 outbreaks. Proc Natl Acad Sci U S A. 2020;117(30):17513-5.
11. Qiu J. Covert coronavirus infections could be seeding new outbreaks.
Nature. 2020.
12. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and
Validation of a Clinical Risk Score to Predict the Occurrence of
Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern
Med. 2020;180(8):1081-9.
13. Zheng X, Luo S, Sun Y, Han M, Liu J, Sun L, et al. Asymptomatic
patients and asymptomatic phases of Coronavirus Disease 2019 (COVID-19):
a population-based surveillance study. National Science Review.
2020;7(10):1527-39.
14. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the
Achilles’ Heel of Current Strategies to Control Covid-19. N Engl J Med.
2020;382(22):2158-60.
15. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et
al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled
Nursing Facility. N Engl J Med. 2020;382(22):2081-90.
16. Baek S, Park SH, Won E, Park YR, Kim HJ. Propensity score matching:
a conceptual review for radiology researchers. Korean J Radiol.
2015;16(2):286-96.
17. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell
landscape of bronchoalveolar immune cells in patients with COVID-19. Nat
Med. 2020;26(6):842-4.
18. Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and
clinical course of asymptomatic cases with COVID-19 pneumonia at
admission in Wuhan, China. J Infect. 2020;81(1):e33-e9.
19. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia
predicts disease severity of COVID-19: a descriptive and predictive
study. Signal Transduct Target Ther. 2020;5(1):33.
20. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and
immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med.
2020;26(8):1200-4.
21. Mendez R, Aldas I, Menendez R. Biomarkers in Community-Acquired
Pneumonia (Cardiac and Non-Cardiac). J Clin Med. 2020;9(2).
22. Karakioulaki M, Stolz D. Biomarkers in Pneumonia-Beyond
Procalcitonin. Int J Mol Sci. 2019;20(8).
23. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM.
Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A
Systematic Review and Meta-analysis. Clin Infect Dis. 2020;70(3):538-42.
24. Lippi G, Plebani M. Procalcitonin in patients with severe
coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta.
2020;505:190-1.
25. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of
critical & mortal COVID-19 cases: A systematic literature review and
meta-analysis. J Infect. 2020;81(2):e16-e25.
26. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A Comparative
Study on the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia
With Other Pneumonias. Clin Infect Dis. 2020;71(15):756-61.
27. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of
Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan,
China. Clin Infect Dis. 2020;71(15):762-8.
28. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional
exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol
Immunol. 2020;17(5):533-5.
29. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492-9.
30. Macon-Lemaitre L, Triebel F. The negative regulatory function of the
lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.
Immunology. 2005;115(2):170-8.